The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones
Open accessAbstract
Biological sex is increasingly recognized as a critical determinant of health and disease, particularly relevant to the topical COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Epidemiological data and observational reports from both the original SARS epidemic and the most recent COVID-19 pandemic have a common feature: males are more likely to exhibit enhanced disease severity and mortality than females. Sex differences in cardiovascular disease and COVID-19 share mechanistic foundations, namely, the involvement of both the innate immune system and the canonical renin-angiotensin system (RAS). Immunological differences suggest that females mount a rapid and aggressive innate immune response, and the attenuated antiviral response in males may confer enhanced susceptibility to severe disease. Furthermore, the angiotensin-converting enzyme 2 (ACE2) is involved in disease pathogenesis in cardiovascular disease and COVID-19, either to serve as a protective mechanism by deactivating the RAS or as the receptor for viral entry, respectively. Loss of membrane ACE2 and a corresponding increase in plasma ACE2 are associated with worsened cardiovascular disease outcomes, a mechanism attributed to a disintegrin and metalloproteinase (ADAM17). SARS-CoV-2 infection also leads to ADAM17 activation, a positive feedback cycle that exacerbates ACE2 loss. Therefore, the relationship between cardiovascular disease and COVID-19 is critically dependent on the loss of membrane ACE2 by ADAM17-mediated proteolytic cleavage. This article explores potential mechanisms involved in COVID-19 that may contribute to sex-specific susceptibility focusing on the innate immune system and the RAS, namely, genetics and sex hormones. Finally, we highlight here the added challenges of gender in the COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109 · cited 1×
“Therapies indicated for the prevention, treatment, or management of CVD include drugs targeting the RAS, namely, angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) (29).”
BackgroundAn inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Chen, L., Li, X., Chen, M., Feng, Y., & Xiong, C. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa078 · Cited by 1,163 · cited 1×
“Therefore, RAS overactivity would promote disease severity, especially for patients with comorbid CVD (43).”
BackgroundLandscape of X chromosome inactivation across human tissues
GTEx Consortium, Tukiainen, T., Villani, A.-C., Yen, A., Rivas, M. A., Marshall, J. L., Satija, R., Aguirre, M., Gauthier, L., Fleharty, M., et al. (2017) · Nature · doi:10.1038/nature24265 · Cited by 1,138
Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure
Patel, V. B., Zhong, J.-C., Grant, M. B., & Oudit, G. Y. (2016) · Circulation Research · doi:10.1161/circresaha.116.307708 · Cited by 833
Self-citationInterplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
Angiotensin Converting Enzyme 2: A Double-Edged Sword
Wang, K., Gheblawi, M., & Oudit, G. Y. (2020) · Circulation · doi:10.1161/circulationaha.120.047049 · Cited by 265 · cited 1×
“ACE2, a counterregulatory monocarboxypeptidase, has garnered enhanced interest as the receptor for SARS-CoV-2 (22, 26, 36).”
BackgroundSelf-citation
Cited by
Viveiros, A., Noyce, R. S., Gheblawi, M., Colombo, D., Bilawchuk, L. M., Clemente-Casares, X., Marchant, D. J., Kassiri, Z., Del Nonno, F., Evans, D. H., et al. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00578.2022 · Cited by 21
Self-citationRafaniello, C., Gaio, M., Zinzi, A., Sullo, M. G., Liguori, V., Ferraro, M., Petronzelli, F., Felicetti, P., Marchione, P., Marra, A. R., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15050525 · Cited by 16
The problem with one-size-fits-all medicine: biological sex and the aging immune system
Baker, C., Ansere, V. A., Sanqui, C. I., & Benayoun, B. A. (2026) · PLOS Biology · doi:10.1371/journal.pbio.3003763 · Cited by 3
Metadata
- Authors
- Viveiros, A., Rasmuson, J., Vu, J., Mulvagh, S. L., Yip, C. Y. Y., Norris, C. M., & Oudit, G. Y.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2021-01-01
- Volume
- 320
- Issue
- 1
- Pages
- H296-H304
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W3109354304
- Cited by
- 173
- References
- 9
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. https://app.cochat.ai/papers/10.1152/ajpheart.00755.2020
- The paper
- Viveiros, A., Rasmuson, J., Vu, J., Mulvagh, S. L., Yip, C. Y. Y., Norris, C. M., & Oudit, G. Y. (2021). Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. American Journal of Physiology-Heart and Circulatory Physiology. https://doi.org/10.1152/ajpheart.00755.2020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.